The costs associated with the diagnosis and treatment of cancer in the UK will dramatically increase by 2021, according to a new report published by private healthcare provider Bupa.

The costs per year could rise to as much as £15.3bn, a 62% increase over the 2010 figure of £9.4bn.

The increases equate to an increase of approximately £10,000 to £40,000 for the average cost of treating someone diagnosed with cancer, representing a significant impact on the nation’s National Health Service.

The report was, however, dismissed by the Department of Health, which issued a statement reading: "Over the past five years, expenditure on cancer has grown no faster than costs for the NHS as a whole."

The report found that the NHS will be dealt the biggest impact, with costs rising by 65% to £5.2bn a year, with the private healthcare sector also witnessing a 65% increase to £531m a year.

Bupa expects demand for cancer diagnosis and treatment to rise by 2% annually over the next decade, with demand for new treatments to steadily rise by 3.7% a year over the same period.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Potential approaches to reduce the impact highlighted by the report include improved national planning for the availability of new and innovative treatments, a rethink of how out-of-hospital care is managed, and enabling patients to transfer between public and private care facilities more easily.